title: [Fosfomycin, co-trimoxazole and nitrofurantoin in the treatment of recurrent uncomplicated urinary tract infections in type 2 diabetes mellitus].
abstract: The aim of this study was to comprise the efficacy of chronic therapy with fosfomycin, co-trimoxazole and nitrofurantoin in the treatment and prevention of recurrent urinary tract infections (UTI) in type 2 diabetic women.
  
  
  METHODS
  The study comprised 90 women aged 50-70 years, who suffered from the UTI (isolated bacterial uropathogen sensitive to fosfomycin, co-trimoxazole and nitrofurantoin). Women were divided into 3 groups. Group I comprised patients, who have been treated with fosfomycin, group II with co-tromixazole and group III with nitrofurantoin. Observation period lasted 9 months and for the 6 months patients were treated with antimicrobial agents. Efficacy of antimicrobial treatment was estimated when both clinical cure and bacteriological eradication of uropathogens were achieved.
  
  
  RESULTS
  There were no significant differences in the percentage of patients between study groups, who achieved therapeutic successes after 3 and 6 months of the antimicrobial treatment (NS). Three months after discontinuation of treatment episodes of UTI were observed significantly rarely in group treated with fosfomycin in comparison with the group treated with nitrofurantoin (p = 0.01) and co-trimoxazole (p = 0.02).
  
  
  CONCLUSIONS
  Fosfomycin, co-trimoxazole and nitrofurantoin are safe and effective antimicrobial methods to cure and prevent UTI. Fosfomycin is associated with rarely recurrence of UTI than nitrofurantoin and co-trimoxazole in the period without its taking.
authors.affiliation: Kliniki Kardiologii Interwencyjnej, Kardiodiabetologii i Rehabilitacji Kardiologicznej, Uniwersytetu Medycznego w Lodzi.
authors.forename: Jan
authors.initials: J
authors.lastname: Ruxer
authors.forename: Michał
authors.initials: M
authors.lastname: Mozdzan
authors.forename: Jerzy
authors.initials: J
authors.lastname: Loba
authors.forename: Leszek
authors.initials: L
authors.lastname: Markuszewski
mesh_terms: D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009582:Nitrofurantoin / Q000627:therapeutic use*; D055502:Secondary Prevention; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology / Q000652:urine; D014556:Urine / Q000382:microbiology
chemical_list: D000892:Anti-Infective Agents, Urinary; D005578:Fosfomycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D009582:Nitrofurantoin